Nuclear Factor of Activated T Cells Is Activated in the Endothelium of Retinal Microvessels in Diabetic Mice

Table 1

A-285222 treatment does not affect plasma cytokine levels in diabetic NFAT-luc mice.

Cytokine; (pg/mL)	Control; ()	STZ; ()	STZ + A-285222; ()
IL-10	22.0 ± 3.6	28.1 ± 7.0	29.4 ± 21.1
TNF-α	0.7 ± 0.3	0.6 ± 0.5	0.2 ± 0.5
IFN-γ	1.3 ± 1.3	1.2 ± 0.5	1.4 ± 0.8
IL-12p70	3.9 ± 5.5	8.2 ± 9.0	32.7 ± 56.2
IL-1β	1.0 ± 0.4	1.2 ± 0.5	1.1 ± 0.8
IL-6	13.3 ± 5.7	16.6 ± 5.8	25.0 ± 22.4
KC	51.4 ± 27.5	56.5 ± 17.7	64.1 ± 53.6

Data expressed as mean ± SD. Plasma cytokine levels (pg/mL) in control and STZ-treated NFAT-luc mice that had been treated with the NFAT inhibitor A-285222 (0.15 mg/kg/day) or saline, measured 2 weeks after the first STZ/vehicle injection. One-way ANOVA revealed no significant differences between groups. Interleukin- (IL-) 10, tumor necrosis factor- (TNF-) α, interferon- (IFN-) γ, IL-12p70, IL-1β, IL-6, and keratinocyte chemoattractant (KC) were measured using multiplex technology.